Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
A phase 2 study of Galunisertib (TGF-beta1 receptor type I Inhibitor) and Sorafenib in patients with advanced hepatocellular carcinoma
Understanding your metabolic response to semaglutideand your individual risk factors for weight regainhelps you have a more informed conversation with your healthcare provider
Dual GIP/GLP-1 agonist for weight management and metabolic regulation
Access limitations or urgent medical need for metabolic control In some real-world cases, patients may face barriers to thyroid care (such as long wait times for endocrinology appointments) but have immediate access to a weight loss or diabetes program that includes GLP-1 medications
US$ 25.45
US$ 21.49
US$ 23.80
US$ 29.27
US$ 23.20
